Nitin Kaila

Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia

Christie M. Ballantyne, Joel Neutel, Anne Cropp et al. · The American Journal of Cardiology · 2015 · 168 citations · Full text

Pharmacokinetics of Ranibizumab after Intravitreal Administration in Patients with Retinal Vein Occlusion or Diabetic Macular Edema

Yi Xin Zhang, Zhenling Yao, Nitin Kaila et al. · Ophthalmology · 2014 · 37 citations

Diabetic Retinopathy, Ocular Disease, Vitreous Body +10

Mixture Models and Subpopulation Classification: A Pharmacokinetic Simulation Study and Application to Metoprolol CYP2D6 Phenotype

Nitin Kaila, Robert J. Straka, Richard C. Brundage · Journal of Pharmacokinetics and Pharmacodynamics · 2006 · 19 citations

Pharmacokinetic Modeling, Mixture Models, Subpopulation Classification +9

=EFFICACY AND SAFETY OF BOCOCIZUMAB (RN316/PF-04950615), A MONOCLONAL ANTIBODY AGAINST PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 IN STATIN-TREATED HYPERCHOLESTEROLEMIC SUBJECTS: RESULTS FROM A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY (NCT: 01592240)

Christie M. Ballantyne, Joel Neutel, Anne Cropp et al. · Journal of the American College of Cardiology · 2014 · 18 citations

Lipid Disorder, Cardiovascular Disease, Safety Of Bococizumab +8

Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar

Jocelyn Courville, Loretta J. Nastoupil, Nitin Kaila et al. · BioDrugs · 2021 · 16 citations · Full text